Lento Bio Announces Official Collaboration With Florida State University and Expansion of Advisory Board

POTSDAM, NY, USA, February 7, 2023/EINPresswire.com-  Lento Bio, an early-stage pharmaceutical research company developing novel small molecule drugs for presbyopia, is proud to announce two major points of progress in assembling the technical and scientific expertise required to further development of its novel pipeline focused on presbyopia and other diseases of aging. These include an […]

Lento Bio Raises $680,000 In Oversubscribed Seed Round Led by Ichor Life Sciences

POTSDAM, NY / September 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, announced today they have raised $680,000 in funding during their recent oversubscribed seed round. Ichor Life Sciences is the lead investor for the round, providing $400,000 in funding to Lento Bio. […]

Lento Bio, An Ichor Life Sciences Portfolio Company, Launches With Aims to Develop Anti-Glycation Drugs for Presbyopia and Diseases of Aging

Potsdam, N.Y. –. Lento Bio, Inc., a preclinical pharmaceutical company focused on developing small-molecule therapeutics to target molecular damage driving age-related disease, announced its launch today. The company will initially focus on developing pharmaceutical eyedrops to treat a common vision disorder, presbyopia, or age-related farsightedness. Lento Bio will be supported and incubated by Ichor Life […]